Compare
NAVs as of 20 Aug 2026
Add a second fund to compare. Until then every figure below is shown against the Other ETFs median (73 funds), which is the only comparison one fund can support.
Growth of ₹100 (rebased over the selected window)
Common period 21 Aug 2020 – 20 Aug 2026, limited by HDFC Nifty Bank ETF. Every series is rebased to ₹100 at the start of this window. Benchmark lines are the category index WealthTicker measures against, which is not always the benchmark the scheme itself declares — the fund page’s Scheme Info names that one.
View as table
| Date | HDFC Nifty Bank ETF | Nifty Bank |
|---|---|---|
| 21 Aug 2020 | ₹100.00 | ₹100.00 |
| 20 Feb 2021 | ₹160.57 | ₹160.73 |
| 21 Aug 2021 | ₹157.25 | ₹157.11 |
| 20 Feb 2022 | ₹168.57 | ₹168.61 |
| 21 Aug 2022 | ₹175.91 | ₹174.83 |
| 20 Feb 2023 | ₹183.50 | ₹182.52 |
| 21 Aug 2023 | ₹199.85 | ₹197.32 |
| 20 Feb 2024 | ₹213.71 | ₹211.19 |
| 20 Aug 2024 | ₹232.26 | ₹227.82 |
| 19 Feb 2025 | ₹226.49 | ₹222.29 |
| 20 Aug 2025 | ₹256.23 | ₹249.77 |
| 19 Feb 2026 | ₹279.20 | ₹272.38 |
| 20 Aug 2026 | ₹265.69 | ₹257.83 |
| Metric | HDFC NAV ₹59.28 Very High risk ★★★☆☆ | Category median Other ETFs · 73 funds |
|---|---|---|
| +3.69% | +4.04% | |
| +10.06% | +10.87% | |
| +11.06% | +9.30% | |
| — | +11.96% | |
| +17.70% | +11.34% | |
| +9.81% | — | |
| +13.59% | +14.16% | |
| +13.69% | +14.63% | |
| — | +13.16% | |
| Risk | ||
| 16.08% | 14.74% | |
| 0.22 | 0.30 | |
| 0.31 | 0.42 | |
| -20.59% | -21.01% | |
| Nifty Bank | — | |
| +0.59% | +0.59% | |
| 1.00 | 1.00 | |
| 100.9% | 100.9% | |
| 97.8% | 97.8% | |
| 0.17% | 0.29% | |
| ₹2,538Cr | ₹143.12Cr | |
| — | — | |
| — | — | |
| — | — | |
| — | — | |
| — | — | |
| Arun Agarwal | — | |
| 21 Aug 2020 | — | |
| 14 | — | |
| 86.7% | — | |
| — | — | |
Best marks the strongest value in a row, and only where the gap is bigger than noise — a near-tie is left unmarked rather than dressed up as a result. SIP XIRR is a ₹10,000/month instalment over 5 years of real NAV history. Nothing here is supplied by a fund house. For research only — not investment advice.